Primary Hyperlipidemia

Esperion Therapeutics announced the FDA approved broad label expansion for bempedoic acid and bempedoic acid/ezetimibe for CV risk reduction and LDL lowering in both primary and secondary prevention populations.

Global cardiovascular mortality increased through 2022, with BP remaining the largest contributor to CVD worldwide, according to an almanac-style report published in the Journal of the American College of Cardiology.

Esperion announced the FDA granted an updated indication for bempedoic acid and bempedoic acid plus ezetimibe for the treatment of primary hyperlipidemia in eligible patients with genetic hyperlipidemia or atherosclerotic CVD.